Clinical evaluation of primary human papillomavirus (HPV) testing with extended HPV genotyping triage for cervical cancer screening: A pooled analysis of individual patient data from nine population-based cervical cancer screening studies from China

被引:4
|
作者
Dun, Changchang [1 ,2 ]
Yuan, Meiwen [2 ]
Zhao, Xuelian [2 ]
Hu, Shangying [2 ]
Arbyn, Marc [3 ]
Zhao, Fanghui [1 ,2 ]
机构
[1] Chinese Acad Med Sci & Peking Union Med Coll, Sch Populat Med & Publ Hlth, Dept Populat Med, Beijing 100730, Peoples R China
[2] Chinese Acad Med Sci & Peking Union Med Coll, Natl Clin Res Ctr Canc, Natl Canc Ctr, Dept Epidemiol,Canc Hosp, Beijing, Peoples R China
[3] Sci Inst Publ Hlth, Belgian Canc Ctr, Unit Canc Epidemiol, Brussels, Belgium
来源
CANCER MEDICINE | 2024年 / 13卷 / 11期
关键词
cervical cancer; HPV genotyping; pooled analysis; screening; triage; INTRAEPITHELIAL NEOPLASIA; RISK; WOMEN; PREVALENCE; INFECTION; METAANALYSIS; PERFORMANCE;
D O I
10.1002/cam4.7316
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objective: To assess the clinical values of extended human papillomavirus (HPV) genotyping in triage of high-risk HPV-positive women, focusing on the trade-off between cervical precancer detections and colposcopy referrals. Methods: A bivariate random-effects model was used to estimate the diagnostic accuracy of primary HPV screening with following triage strategies to detect cervical precancers: (i) partial genotyping for HPV16/18 combined with cytological testing at atypical squamous cells of undetermined significance threshold (used as the comparator), (ii) genotyping for HPV16/18/58/52, (iii) genotyping for HPV16/18/58/52/33, (iv) genotyping for HPV16/18/58/33/31, (v) genotyping for HPV16/18/58/52/33/31, and (vi) genotyping for HPV16/18/58/52/33/31/39/51. Internal risk benchmarks for clinical management were used to evaluate the risk stratification of each triage strategy. Results: A total of 16,982 women (mean age 46.1 years, range 17-69) were included in this analysis. For CIN3+ detection, triage with HPV16/18/58/33/31 genotyping achieved lower positivity (6.85% vs. 7.35%, p = 0.001), while maintaining similar sensitivity (91.35% vs. 96.42%, p = 0.32) and specificity (94.09% vs. 93.67%, p = 0.56) compared with the comparator strategy. Similar patterns were observed for CIN2+ detection. Women with a positive HPV16/18/58/33/31 genotyping test had high enough risk for CIN3+ for colposcopy referral, while the risk for women with a negative test was below the 1-year return decision threshold according to internal benchmarks. Conclusions: Our findings suggested extended HPV genotyping is of potential to be used as a triage technique integrated into HPV-based cervical cancer screening, leading to reduced need for colposcopy referral while maintaining similar disease detection and efficient risk stratification.
引用
收藏
页数:15
相关论文
共 50 条
  • [1] Liquid-based cytology and human papillomavirus testing: A pooled analysis using the data from 13 population-based cervical cancer screening studies from China
    Pan, Qin-jing
    Hu, Shang-ying
    Guo, Hui-qin
    Zhang, Wen-hua
    Zhang, Xun
    Chen, Wen
    Cao, Jian
    Jiang, Yong
    Zhao, Fang-hui
    Qiao, You-lin
    GYNECOLOGIC ONCOLOGY, 2014, 133 (02) : 172 - 179
  • [2] Primary Screening for Cervical Cancer Based on High-Risk Human Papillomavirus (HPV) Detection and HPV 16 and HPV 18 Genotyping, in Comparison to Cytology
    Agorastos, Theodoros
    Chatzistamatiou, Kimon
    Katsamagkas, Taxiarchis
    Koliopoulos, George
    Daponte, Alexandros
    Constantinidis, Theocharis
    Constantinidis, Theodoros C.
    PLOS ONE, 2015, 10 (03):
  • [3] Evaluation of p16INK4a immunocytology and human papillomavirus (HPV) genotyping triage after primary HPV cervical cancer screening on self-samples in China
    Song, Fangbin
    Belinson, Jerome L.
    Yan, Peisha
    Huang, Xia
    Wang, Chun
    Du, Hui
    Qu, Xinfeng
    Wu, Ruifang
    GYNECOLOGIC ONCOLOGY, 2021, 162 (02) : 322 - 330
  • [4] The Role of Human Papillomavirus Genotyping in Cervical Cancer Screening: A Large-Scale Evaluation of the cobas HPV Test
    Schiffman, Mark
    Boyle, Sean
    Raine-Bennett, Tina
    Katki, Hormuzd A.
    Gage, Julia C.
    Wentzensen, Nicolas
    Kornegay, Janet R.
    Apple, Raymond
    Aldrich, Carrie
    Erlich, Henry A.
    Tam, Thanh
    Befano, Brian
    Burk, Robert D.
    Castle, Philip E.
    CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2015, 24 (09) : 1304 - 1310
  • [5] HPV-based cervical cancer screening in Nicaragua: from testing to treatment
    Holme, Francesca
    Maldonado, Francisco
    Martinez-Granera, Orlando B.
    Rodriguez, Jose Maria
    Almendarez, Juan
    Slavkovsky, Rose
    Bansil, Pooja
    Thomson, Kerry A.
    Jeronimo, Jose
    de Sanjose, Silvia
    BMC PUBLIC HEALTH, 2020, 20 (01)
  • [6] Clinical evaluation of human papillomavirus 16/18 oncoprotein test for cervical cancer screening and HPV positive women triage
    Yu, Lulu
    Jiang, Mingyue
    Qu, Pengpeng
    Wu, Zeni
    Sun, Peisong
    Xi, Mingrong
    Qin, Yu
    Liu, Xin
    Liao, Guangdong
    Lei, Xiaoqin
    Sun, Lixin
    Zhang, Yongzhen
    Li, Zhifang
    Chen, Wen
    Qiao, You-Lin
    INTERNATIONAL JOURNAL OF CANCER, 2018, 143 (04) : 813 - 822
  • [7] Human papillomavirus (HPV) DNA and mRNA primary cervical cancer screening: Evaluation and triaging options for HPV-positive women
    Sangrajrang, Suleeporn
    Laowahutanont, Piyawat
    Wongsena, Metee
    Muwonge, Richard
    Imsamran, Weerawut
    Ploysawang, Pattama
    Basu, Partha
    JOURNAL OF MEDICAL SCREENING, 2019, 26 (04) : 212 - 218
  • [8] Human papillomavirus-based screening at extended intervals missed fewer cervical precancers than cytology in the HPV For Cervical Cancer (HPV FOCAL) trial
    Gottschlich, Anna
    Gondara, Lovedeep
    Smith, Laurie W.
    Cook, Darrel
    Martin, Ruth Elwood
    Lee, Marette
    Peacock, Stuart
    Proctor, Lily
    Stuart, Gavin
    Krajden, Mel
    Franco, Eduardo L.
    van Niekerk, Dirk
    Ogilvie, Gina
    INTERNATIONAL JOURNAL OF CANCER, 2022, 151 (06) : 897 - 905
  • [9] Cervical Cancer Screening Programs in Europe: The Transition Towards HPV Vaccination and Population-Based HPV Testing
    Chrysostomou, Andreas C.
    Stylianou, Dora C.
    Constantinidou, Anastasia
    Kostrikis, Leondios G.
    VIRUSES-BASEL, 2018, 10 (12):
  • [10] Performance of high-risk human papillomavirus DNA testing as a primary screen for cervical cancer: a pooled analysis of individual patient data from 17 population-based studies from China
    Zhao, Fang Hui
    Lin, Margaret Jane
    Chen, Feng
    Hu, Shang Ying
    Zhang, Rong
    Belinson, Jerome L.
    Sellors, John W.
    Franceschi, Silvia
    Qiao, You Lin
    Castle, Philip E.
    LANCET ONCOLOGY, 2010, 11 (12) : 1160 - 1171